Genetic Technologies Ltd. engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 58 full-time employees. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its EasyDNA brand. The company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The firm has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The firm's segments include EasyDNA, AffinityDNA, and GeneType/Corporate. The EasyDNA segment relates to EasyDNA branded test sales and expenses. The AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType/Corporate: relates to geneType branded test sales and expense, includes corporate charges.
GNTLF stock price ended at $0 on 金曜日, after dropping 100.00%
On the latest trading day Jul 25, 2025, the stock price of GNTLF fell by 100.00%, dropping from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. On the latest trading day, the trading volume for GNTLF rose by 1.9K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 2.0K shares were traded, with a market value of approximately --.
Comment les indicateurs d'analyse technique s'appliquent-ils à GNTLF ?
Selon l'analyse technique, Genetic Technologies Limited a un signal agrégé de Neutral. Genetic Technologies Limited a 0 signaux d'achat, 7 signaux neutres et 0 signaux de vente.
Quel est le RSI de Genetic Technologies Limited ?
Le RSI de Genetic Technologies Limited est actuellement de NaN, indiquant une condition 中立
Quel est le prix de Genetic Technologies Limited pour les 12 prochains mois ?
Le prix de Genetic Technologies Limited GNTLF pour les 12 prochains mois est estimé à $0.